Interim data from the ongoing EPITOME trial1 showed that 45.7% of stroke survivors with paresis developed post-stroke spasticity within 1 year<1% of stroke survivors receive BoNT-A treatment for ...

Two-year follow up of FLT201 AAV gene therapy in adults with Type 1 Gaucher Disease: Results from GALILEO-1 and GALILEO-2 Session: Clinical Applications Date & Time: Thursday, February 5, 9:30 a.m.

WALTHAM, Mass. & DURHAM, N.C.--(BUSINESS WIRE)--Life Edit ® Therapeutics Inc., an ElevateBio ® company focused on next-generation gene editing technologies and therapeutics, today announced the ...

Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorderBOSTON and LONDON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Centessa ...

HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”) will publicly present, for the first time, clinical results from the Phase 1 study of TTI-101, a STAT3 inhibitor, in relapsed/refractory ...

Perspective continues to make progress on expanding its manufacturing capabilities by increasing and enhancing capacity at existing facilities and building out recently acquired sites.

Pasithea has completed enrollment of 12 patients through the first 4 dose cohorts (4, 8, 12 and 18 mg tablets) in Part A of the study.

Data visualization is a process in data analytics where visual representation communicates the data and insights to facilitate good data-driven decisions. Basically, data visualization is ...

Complete list of Ipsen presentations at TOXINS 2026: ...